Shandong Weigao Group Medical Polymer Company Limited Goes Ex Dividend Monday
The significant decline in performance is due to the price reduction of centrally purchased products. The chunli medical investment projects are generally delayed. | Directly hit the earnings conference.
Regarding the main reasons for the decline in revenue and net income, Chunli Medical stated that it was due to the impact of the implementation of the national high-value medical consumables volume-based procurement, which led to a decrease in the selling price of related products. Chunli Medical announced that, except for the replenishment project, the availability of the other four projects funded by the IPO has been adjusted with a delay.
Shandong Weigao Group Medical Polymer Company Limited Goes Ex Dividend Tomorrow
Global X MSCI China Health Care ETF Declares Semi-annual Distribution of $0.0283
KraneShares MSCI All China Health Care Index ETF Declares $0.1128 Dividend
Nuohui Health falsifies Rashomon's regeneration with twists and turns: shorting reveals more investigation details
Is it the end?
股市-老道士 : It's right to pay attention to this section